{"id":845912,"date":"2025-05-02T07:34:32","date_gmt":"2025-05-02T11:34:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-to-present-at-14th-international-bmp-conference-highlighting-advances-in-regenerative-biologics\/"},"modified":"2025-05-02T07:34:32","modified_gmt":"2025-05-02T11:34:32","slug":"darnatein-to-present-at-14th-international-bmp-conference-highlighting-advances-in-regenerative-biologics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/darnatein-to-present-at-14th-international-bmp-conference-highlighting-advances-in-regenerative-biologics\/","title":{"rendered":"Darnatein to Present at 14th International BMP Conference Highlighting Advances in Regenerative Biologics"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n PHILADELPHIA<\/span>
\n <\/span>, May 2, 2025<\/span><\/span> \/PRNewswire\/ — Darnatein<\/b>, a subsidiary of OSR Holdings, Inc.<\/b> (NASDAQ: OSRH), a biotechnology company advancing design-augmented biologics, announced today that it will present scientific data at the 14th International Bone Morphogenetic Protein (BMP) Conference<\/b>, taking place May 2\u20136, 2025<\/b>, at the University of Pennsylvania<\/span><\/b> in Philadelphia<\/span>.<\/p>\n

\n

\n
\n \"OSR
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The BMP Conference brings together leading global researchers to explore the latest breakthroughs in BMP-related biology and regenerative medicine. This year’s program highlights novel technologies and fundamental research in tissue and organ regeneration. (https:\/\/www.14thbmpconference2025.com\/<\/a>)<\/p>\n

\n Dr. Senyon “Teddy” Choe<\/b>, CEO of Darnatein, will deliver a scientific presentation on May 3<\/span><\/b>, titled:
“Design-Augmented Synthetic BMP Chimeras as Super-Agonists for Bone and Cartilage Regeneration.”<\/b><\/p>\n

The presentation will showcase Darnatein’s proprietary platform technology that has led to the development of DRT-101<\/b> and DRT-102<\/b>, two novel biologic candidates engineered to function as BMP super-agonists. DRT-101 with good preclinical safety profiles is being developed for joint cartilage regeneration<\/b>, while DRT-102 is focused on spinal bone repair<\/b>.<\/p>\n

“This presentation reflects Darnatein’s growing leadership in synthetic regenerative biologics,” said Dr. Choe. “Our DA Biologics platform is enabling the creation of highly potent, next-generation growth factors with potential to transform musculoskeletal repair.”<\/p>\n

Darnatein’s participation at the BMP Conference underscores a year of significant progress, including:<\/p>\n